GWS
XFOR icon

Glassman Wealth Services’s X4 Pharmaceuticals XFOR Stock Holding History

Glassman Wealth Services’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed -$3K – 1683
2021
Q1 		$3K Buy
10
+2
+25% +$526 ﹤0.01% 1034
2020
Q4 		$2K Buy
+8
New +$1.57K ﹤0.01% 1116

Other funds holding XFOR

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Glassman Wealth Services's XFOR Position: Q2 2021 in Review

Glassman Wealth Services sold out of X4 Pharmaceuticals (XFOR) in Q2 2021, closing a stake of 10 shares — an estimated $3K sold.

Glassman Wealth Services first reported a position in XFOR in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 62 funds tracked by Wall St. Rank hold XFOR as of Q2 2021.

  • Glassman Wealth Services reported no remaining X4 Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 10 X4 Pharmaceuticals shares in Q2 2021, an estimated $3K.
  • Glassman Wealth Services first reported a position in X4 Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Glassman Wealth Services's X4 Pharmaceuticals position peaked at $3K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2021.

Based on Glassman Wealth Services's 13F filing for Q2 2021, filed 4 Aug 2021.